Report
Clinical and cost utility evaluation of glucagon-like peptide 1 analogues for the treatment of type 2 diabetes in the Australian setting
An Tran-Duy, Tessa Peasgood, Patrick Abraham, Philip Clarke
Published : 2021
Abstract
In this project commissioned by the Australian Government Department of Health and Aged Care, we aimed to (1) provide the best available evidence to support the effectiveness and safety assessment of glucagon-like peptide 1 receptor agonists (GLP-1 RAs), particularly in comparison to sulfonylureas in treating patients with type 2 diabetes mellitus, and (2) conduct a cost-utility analysis and cost-effectiveness analysis of GLP-1 RAs compared to sulfonylureas using the UKPDS Outcomes Model version 2.